Dataset Information

Association between gender inequality and population-level health outcomes: Panel data analysis of organization for Economic Co-operation and Development (OECD) countries.

ABSTRACT:

Background

Gender plays a well-recognized role in shaping health inequities. However, the population-level health consequences of gender inequalities have not been measured comprehensively. The goal of this study was to evaluate the association between gender inequality and health indicators in organization for Economic Co-operation and Development (OECD) countries.

Methods

Ecological study based on 1990-2017 panel data for OECD member countries. Gender inequality was measured using the Gender Inequality Index (GII). The population health parameters evaluated were life expectancy (LE), healthy life expectancy (HALE), years of life lost (YLL), years lived with disability (YLD), disability-adjusted life years (DALYs), and specific-cause mortality. Two-way fixed-effects linear models were used to assess the relationship between gender inequality and health outcomes. Models included potential mediating and confounding factors such as health spending, political model, and income inequalities.

Findings

Greater gender inequality was associated with lower LE (-0·49%; CI₉₅ -0·63%- -0·31%; p-value < 0·0001), HALE (-0·47%; CI₉₅ -0·63%- -0·31%; p-value < 0·0001) and with increased premature mortality YLL (6·82%; CI₉₅ 3·63%-10·75%; p-value < 0·0001) and morbidity measured in DALYs (1·50%; CI₉₅ 0·48%-2·46%; p-value = 0·0028) and YLD (2·59%; CI₉₅ 0·67%-4·77%; p-value = 0·0063) for each 0·1 increments on the GII. The sensitivity analysis indicated that the results were robust to the various specifications of the causal models.

Interpretation

Our results suggest that gender inequality pose a sizable impact on population health outcomes. Promoting gender equality as part of public policies is vital for optimizing health on a population scale.

Funding

Agencia Nacional de Investigación y Desarrollo (ANID)/Programa Becas/Magister Becas Chile/2017- 22,170,332.

SUBMITTER: Veas C

PROVIDER: S-EPMC8342902 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundChronic migraine (CM) is a significant neurological condition affecting a substantial portion of the global population. The economic burden of CM includes both direct healthcare costs and indirect costs resulting from productivity losses and intangible impacts on patients' quality of life. However, there is limited research that comprehensively evaluates all cost components associated with CM, highlighting the need for a systematic review.MethodsWe conducted a systematic literature search in databases including MEDLINE, Embase, and CINAHL to identify studies estimating the cost of illness of chronic migraines. The search was restricted to English language articles published from inception to October 2021, and only findings from Organisation for Economic Co-operation and Development (OECD) countries were included. Methodology features and key findings were extracted from the studies, and reported costs were converted to GBP for cross-country comparisons.ResultsThirteen cost-of-illness studies on CM from various OECD countries were included in this review. The studies demonstrated substantial variations in monetary estimates, but consistently highlighted the considerable economic burden of CM. Direct costs, particularly hospitalisation and medication expenses, were identified as the highest contributors. However, indirect costs, such as productivity losses due to absenteeism and presenteeism, were often underexplored in the reviewed studies. Additionally, intangible costs related to emotional and social impacts on patients were largely overlooked.ConclusionChronic migraine imposes a significant economic burden on individuals, healthcare systems, and society. Policymakers and healthcare stakeholders should consider both direct and indirect cost components, as well as intangible costs, in developing targeted strategies for effective CM management and resource allocation. Further research focusing on comprehensive cost assessments and sensitivity analyses is needed to enhance the understanding of CM's economic implications and inform evidence-based healthcare policy decisions. Addressing these research gaps can alleviate the economic burden of CM and improve patient outcomes.